Results 21 to 30 of about 5,480 (216)

Increasing smoking intensity is associated with increased disease activity in axial spondyloarthritis. [PDF]

, 2016
A history of ever-smoking appears to be associated with a more severe disease phenotype in axial spondyloarthritis (axSpA). However, evidence is sparse for the effect of increased smoking exposure on disease outcomes or whether smoking reduction or ...
Challoner, B, Goodson, NJ, Khattak, M, Moots, RJ, Zhao, S   +4 more
core   +3 more sources

Association of ankylosing spondylitis activity indicators in a Russian population of patients with STAT4 rs7574865 gene polymorphism

Современная ревматология, 2019
Family and twin studies have shown that ankylosing spondylitis (AS) has a hereditary nature that is based on a strong association with the leukocyte antigen HLA-B27.
M. Yu. Krylov, A. S. Starkova, E. Yu. Samarkina, T. V. Dubinina, Sh. F. Erdes   +4 more
doaj   +1 more source

Disease activity indexes might not capture the same disease aspects in males and females with ankylosing spondylitis: A real-world nationwide analysis

Frontiers in Medicine, 2022
BackgroundTo evaluate gender differences in disease activity and health status (HS) in patients with radiographic axial spondyloarthritis (r-axSpA)/ankylosing spondylitis (AS).MethodsAncillary analysis of the MIDAS study, an observational, non ...
Cristina Fernández-Carballido, Vega Jovaní, Emma Beltrán Catalán, Manuel José Moreno-Ramos, Jesús Sanz Sanz, Adela Gallego, M. Luz García Vivar, José Manuel Rodríguez-Heredia, Cristina Sanabra, Carlos Sastré   +9 more
doaj   +1 more source

Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force [PDF]

, 2013
Background: Therapeutic targets have been defined for diseases like diabetes, hypertension or rheumatoid arthritis and adhering to them has improved outcomes. Such targets are just emerging for spondyloarthritis (SpA). Objective: To define the treatment
Baraliakos, Xenofon, Betteridge, Neil, Braun, Jürgen, Burgos-Vargas, Ruben, Collantes-Estevez, Eduardo, de Wit, Martinus, Deodhar, Atul, Dougados, Maxime, Elewaut, Dirk, Emery, Paul, FitzGerald, Oliver, Gossec, Laure, Helliwell, Philip, Jongkees, Merryn, Kavanaugh, Arthur, Kvien, Tore K, Landewé, Robert, Luger, Thomas, Maccarone, Mara, Mease, Philip, Olivieri, Ignazio, Redlich, Kurt, Reveille, John, Ritchlin, Christopher, Rudwaleit, Martin, Schoels, Monika, Sieper, Joachim, Smolen, Josef S, Van den Bosch, Filip, van der Heijde, Désirée, Wei, James Cheng-Chung, Winthrop, Kevin   +31 more
core   +2 more sources

Sustained low functional impairment in axial spondyloarthritis (axSpA): which are the primary outcomes that should be targeted to achieve this?

Arthritis Research & Therapy, 2023
Objectives To (i) determine whether sustained disease activity states, as measured by Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Ankylosing Spondylitis Disease Activity Score (ASDAS), impact function, and (ii) evaluate ...
Walter P. Maksymowych, Robert D. Inman, Louis Bessette, Proton Rahman, Emmanouil Rampakakis, Odalis Asin-Milan, Meagan Rachich, Anne Marilise Marrache, Allen J. Lehman   +8 more
doaj   +1 more source

Persistencia de medicamentos biológicos durante ocho años en pacientes con artritis reumatoide y espondiloartritis [PDF]

, 2019
Objective: To calculate the persistence, over a period of eight years, the retention rate of first and second-line of treatment with biological agents in patients with rheumatoid arthritis, spondyloarthritis and psoriatic arthritis and to compare ...
Balsa, Alejandro, González-Fernández, María, Herrero, Alicia, Jiménez-Nácher, Inmaculada, Moreno, Francisco, Villamañán, Elena   +5 more
core   +3 more sources

Efficacy of Guselkumab on Axial-Related Symptoms Through up to 2 Years in Adults with Active Psoriatic Arthritis in the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Study

Rheumatology and Therapy, 2023
Introduction Guselkumab previously showed greater improvements versus placebo in axial symptoms in patients with psoriatic arthritis (PsA) (assessed by Bath Ankylosing Spondylitis Disease Activity Index [BASDAI] and Ankylosing Spondylitis Disease ...
Philip J. Mease, Dafna D. Gladman, Denis Poddubnyy, Soumya D. Chakravarty, May Shawi, Alexa P. Kollmeier, Xie L. Xu, Stephen Xu, Atul Deodhar, Xenofon Baraliakos   +9 more
doaj   +1 more source

Alcohol and disease activity in axial spondyloarthritis: a cross-sectional study [PDF]

, 2018
The objective of this study was to explore associations between alcohol consumption and disease activity in axial spondyloarthritis (axSpA). We conducted a cross-sectional study of axSpA participants meeting the ASAS criteria.
Duffield, Stephen J, Goodson, Nicola J, Hughes, David, Thong, Daniel, Zhao, Sizheng   +4 more
core   +1 more source

Nonsteroidal Antiinflammatory Drug Use and Association With Incident Hypertension in Ankylosing Spondylitis. [PDF]

, 2020
ObjectiveNonsteroidal antiinflammatory drugs (NSAIDs) increase blood pressure and potentially cardiovascular burden, which may limit their use in ankylosing spondylitis (AS).
Brown, Matthew A, Gensler, Lianne S, Heckbert, Susan R, Lee, MinJae, Liew, Jean W, Rahbar, Mohammed, Reveille, John D, Ward, Michael M, Weisman, Michael   +8 more
core   +1 more source

Randomized controlled trial of adalimumab in patients with nonpsoriatic peripheral spondyloarthritis [PDF]

, 2015
Objective. To evaluate the efficacy and safety of adalimumab in patients with active nonpsoriatic peripheral spondyloarthritis (SpA). Methods. ABILITY-2 is an ongoing phase III, multicenter study of adalimumab treatment.
Karunaratne, P Mahinda, Mease, Philip, Pangan, Aileen L, Rahman, Proton, Sieper, Joachim, Van den Bosch, Filip   +5 more
core   +1 more source